---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-064983"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:16:29.137735+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# EyePoint Q1 net loss $45.2M; DURAVYU Phase 3 wet AMD enrollment over 90% in LUGANO, >50% in LUCIA

## Summary
- Total net revenue $24.5M (up from $11.7M YoY); net loss $45.2M ($0.65 per share) vs $29.3M ($0.55) prior year.
- Cash, equivalents, and marketable securities $318.2M; runway into 2027 past Phase 3 topline data expected 2H 2026.
- LUGANO trial >90% enrolled, LUCIA >50%; enrollment on track to complete 2H 2025.
- Phase 2 VERONA in DME met endpoints; subgroup showed BCVA +10.3 letters vs +3.0 for aflibercept at week 24.

## SEC filing metadata
- accession: 0000950170-25-064983
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017025064983/0000950170-25-064983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017025064983/eypt-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-064983
- JSON: https://secwatch.observer/filing/0000950170-25-064983.json
- Plain text: https://secwatch.observer/filing/0000950170-25-064983.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.